Search Results
Your search for ,Per matches 4038 pages
Showing 1 - 50Relapsed or Refractory CTCL: Denileukin Diftitox May Improve HRQoL
Patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL) receiving denileukin diftitox-cxdl demonstrated an improvement or maintenance of their overall health-related quality of life (HRQoL), according to findings from Study 302 presented at the European Organisation for Research and...
Preventing Africa’s Coming Cancer Crisis: The Harm Reduction Imperative
Africa is heading toward a cancer catastrophe, and the oncology community must not look away. Noncommunicable diseases already account for 37% of all deaths in the WHO African Region, up from 24% in 2000, and nearly two-thirds of these deaths occur prematurely, before 70.1,2These are not distant...
Nobel Prize in Physiology or Medicine 2026 Awarded for Optogenetics
The Nobel Assembly at Karolinska Institutet has awarded the 2026 Nobel Prize in Physiology or Medicine jointly to Karl Deisseroth, MD, PhD, of The Howard Hughes Medical Institute and Stanford University, California; Peter Hegemann, PhD, of Humboldt University of Berlin, Germany; and Georg Nagel,...
U.S. Food and Drug Administration Expanded Indications and Approvals in Bladder and Colorectal Cancers
Several approvals by the U.S. Food and Drug Administration (FDA) over the past month included therapeutics for patients with BCG-unresponsive non–muscle-invasive bladder cancer and locally advanced rectal cancer. Nogapendekin Alfa Inbakicept in BCG-Unresponsive NMIBC On October 14, 2026, the FDA...
Two ‘Forever Chemicals’ Associated With Higher Risk of ER-Negative Breast Cancer
Higher blood concentrations of two common per- and polyfluoroalkyl substances (PFAS) were associated with an increased incidence of estrogen receptor (ER)-negative breast cancer among women participating in the Sister Study, according to research published by Chang et al in the Journal of Clinical ...
Methylphenidate May Reduce Cancer-Related Fatigue in Patients With Hematologic Malignancies
Treatment with the norepinephrine-dopamine reuptake inhibitor methylphenidate significantly reduced cancer-related fatigue in patients with hematologic malignancies compared with placebo, according to findings from the randomized, double-blind, crossover MICRO trial reported by Frederiksen et al in ...
Ponatinib/Blinatumomab Improves Event-Free Survival in Ph-Positive ALL
A chemotherapy-free front-line regimen of ponatinib plus blinatumomab significantly improved event-free survival compared with imatinib plus chemotherapy in adults with newly diagnosed Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL). Chiaretti et al reported results from...
Study Reveals Distinct Cellular and Genetic Differences in Early-Onset Colorectal Cancer
Mass General Brigham researchers from the Gene Lay Institute of Immunology and Inflammation, along with researchers at Dana-Farber Cancer Institute and the Broad Institute, have identified biological differences in colorectal tumors that may help explain why the disease can behave more aggressively ...
ASTRO Updates Guideline on Shorter-Course Radiation Therapy for Localized Prostate Cancer
An updated clinical guideline from the American Society for Radiation Oncology (ASTRO) provides evidence-based recommendations on the use of hypofractionated radiation therapy for patients with localized prostate cancer. The guideline replaces ASTRO’s 2018 recommendations and reflects a...
How Medicare Advantage and Traditional Medicare Influence Palliative and Hospice Care Implementation
In 2024, ASCO updated its guideline for the integration of palliative care in oncology, which recommends that clinicians refer patients with advanced solid tumors and hematologic malignancies to specialized interdisciplinary palliative care teams beginning early in the course of a patient’s disease ...
Impact of Digital Breast Tomosynthesis on Invasive Interval Breast Cancer Rate
Breast cancer screening with digital breast tomosynthesis plus synthesized two-dimensional mammography resulted in fewer invasive interval breast cancers over 2 years than standard digital mammography, although the difference did not reach statistical significance. Weigel et al reported the...
Omega-3 EPA Linked to Longer Survival After Surgery for Colorectal Cancer Liver Metastases
Patients assigned to receive high-dose eicosapentaenoic acid (EPA), an omega-3 fatty acid, before and after surgery for colorectal cancer liver metastases had longer overall survival than those assigned to receive placebo, according to results of the phase III EMT2 trial presented at the European...
FDA Grants Traditional Approval to Pembrolizumab for TMB-H Solid Tumors
On October 16, 2026, the U.S. Food and Drug Administration (FDA) granted traditional approval to pembrolizumab (Keytruda) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex) for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden–high...
Financial Incentives Increase Smoking Abstinence Among Those Referred for Lung Cancer Screening
Among medically underserved adults who smoked and were referred for lung cancer screening, the addition of financial incentives to usual care and free pharmacotherapy significantly increased rates of sustained tobacco abstinence compared with usual care alone or usual care plus free...
Patient-Friendly Research Summaries Spotlight Advances in Pancreatic Cancer
The science and practice of translation is about more than moving discoveries from the lab to the clinic. It also helps break down barriers to access so crucial developments in cancer care can reach patients and improve outcomes all over the world. To help you spread the word about these...
Remote Expert Case Reviews Identify Opportunities to Improve Cancer Care and Reduce Costs
Remote expert review of oncology cases may help to address and improve gaps in evidence-based cancer care, while also providing measurable cost savings, according to findings presented in a poster at the 2026 ASCO Quality Care Symposium (Abstract 700). “Last year at ASCO's Quality Care Symposium,...
FDA Approves Dostarlimab for MSI-H/dMMR Locally Advanced Rectal Cancer
On October 19, 2026, the U.S. Food and Drug Administration (FDA) granted an accelerated approval to the PD-1 inhibitor dostarlimab (Jemperli) for the treatment of adult patients with stage II/III locally advanced rectal cancer that is microsatellite instability–high (MSI-H) or mismatch repair...
ASH Issues New Recommendations for the Management of Myelofibrosis
The American Society of Hematology (ASH) released new guidelines on the management of myelofibrosis which recommend expanded molecular testing, early transplant referral, appropriate use of JAK inhibitors, and aspirin therapy in select patients. The guidelines were published by Stein et al in Blood ...
Iberdomide Triplet Improves MRD-Negative Complete Response in Relapsed/Refractory Multiple Myeloma
Iberdomide combined with daratumumab and dexamethasone nearly doubled the rate of minimal residual disease (MRD)-negative complete response compared with daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma. Lonial et al reported the primary MRD...
Sitagliptin Added to Standard Prophylaxis Reduces Risk of Acute GVHD Following Alternative Donor Transplantation
Adding the selective, oral dipeptidyl peptidase-4 inhibitor, sitagliptin, to antithymocyte globulin–based prophylaxis significantly reduced the incidence of grade 2 to 4 acute graft-vs-host disease (GVHD) among patients undergoing alternative donor hematopoietic stem-cell transplantation, according ...
ACS Report Highlights Cancer Burden and Screening Disparities in U.S. Hispanic Population
The cancer distribution in the Hispanic population is distinct from the general population in the United States, according to a statistics report from the American Cancer Society (ACS) published in CA: A Cancer Journal for Clinicians. The report indicated fewer lung and urinary bladder cancers,...
Wildfire-Related Fine Particulate Matter Linked to Higher Mortality in Older Patients With Lung Cancer
Long-term exposure to fine particulate matter from wildfire smoke was associated with a higher risk of death among older patients with lung cancer, and wildfire-related particulate matter appeared more harmful than nonwildfire air pollution at the same exposure level. Zhang et al reported the...
Global Gaps in Cancer-Control Expenditure Data Identified
There is a large global gap in expenditure data on cancer control, and available data suggest generally low and unequal expenditure across countries and territories, according to a cross-sectional analysis published by Figi et al in The Lancet �Oncology. “The paucity of publicly available...
Annual Report to the Nation: Progress Against Lung Cancer Drives Down Cancer Mortality
Cancer death rates fell for both men and women from 2019 to 2023, continuing a downward trend that has lasted more than 20 years, according to the 2026 Annual Report to the Nation on the Status of Cancer, published by Henley et al in the journal Cancer. The continued decline in cancer deaths is...
Can Long Distance Running Be a Risk Factor for Early-Onset Colorectal Cancer?
Colorectal cancer, once thought of as mainly a disease of the aging, is rising in younger adults by nearly 3% per year and is now a leading cause of cancer-related death among individuals under the age of 50.1 According to the American Cancer Society, in 2026, nearly 159,000 individuals will be...
Multicancer Early Detection Screening Does Not Reduce Overall Late-Stage Cancer Diagnosis
The results of the randomized NHS-Galleri trial reported by Sasieni et al in The New England Journal of Medicine showed that annual screening with a blood-based multicancer early detection test added to usual care did not result in a significantly lower incidence rate of stage III or IV cancers...
Excess Mortality Halts Trial of Venetoclax Added to DA-EPOCH-R in Double-Hit Lymphoma
Adding venetoclax to dose-adjusted EPOCH-R (DA-EPOCH-R) did not improve progression-free survival and resulted in excess toxicity and mortality among patients with newly diagnosed double-hit lymphoma, prompting early closure of the double-hit lymphoma cohort of the randomized ALLIANCE A051701...
Losing Weight and Breast Cancer Risk? The GLP-1 RA Question
The rapid adoption of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for obesity and diabetes has sparked interest in their potential effects on breast cancer risk and outcomes. At the 2026 ASCO Annual Meeting, investigators presented several observational studies examining the relationship...
TMC-I Regimen May Expand Treatment Access in Advanced Head and Neck Cancer
A lower-cost chemoimmunotherapy approach including oral triple metronomic chemotherapy (TMC) combined with ultra-low-dose immunotherapy termed TMC-I could extend survival for patients with advanced head and neck squamous cell carcinoma in resource-limited countries, according to investigators from...
Alcohol-Attributable Cancer Deaths More Than Double in the United States
Cancer mortality associated with alcohol use has risen in the United States, disproportionately affecting males and adults aged at least 55 years, according to a population-based observational trend analysis published by Jani et al in The Lancet Regional Health – Americas. “Our findings highlight...
Independent Validation Supports Prognostic Value of Computational TILs in Triple-Negative Breast Cancer
In the large, platform-based, independent validation study CATALINA, published by Dixon-Douglas et al in The Lancet Oncology, two artificial intelligence (AI)-derived computational tumor-infiltrating lymphocyte (cTIL) models, which were deployed without retraining or modification, provided...
American Cancer Society Urges Men to Understand Their Risk for Prostate Cancer
This September, in honor of Prostate Cancer Awareness Month, the American Cancer Society is encouraging men to discuss their risks of prostate cancer with their doctors and the possibility of screening. The American Cancer Society noted that cases of prostate cancer have continued to increase by...
New NCCN Survey Highlights Persistent Cancer Drug Shortages
The National Comprehensive Cancer Network® (NCCN®) recently published updated data on the current impact of generic cancer medication shortages in the United States. The data come from survey responses from pharmacy directors and other clinical and administrative leadership at NCCN Member...
Structured Exercise After Adjuvant Chemotherapy for Colon Cancer Improves Survival and Saves Costs
A structured exercise program after adjuvant chemotherapy for colon cancer improved survival and saved money. In a preplanned cost-utility analysis of the phase III CHALLENGE trial, presented at the 2026 ASCO Annual Meeting1 and published simultaneously in the Journal of Clinical Oncology,2 the...
Robert A. Kyle, MD, Myeloma Expert, Dies at 98
The International Myeloma Foundation (IMF) shared news of the passing of Robert A. Kyle, MD, at age 98 on September 2, 2026. Dr. Kyle was a highly revered expert in the field of myeloma research and known to many as the “Father of Myeloma” for his groundbreaking work in hematology. Dr. Kyle was...
FDA Approves Camizestrant Combination Regimen for Locally Advanced or Metastatic Breast Cancer
On September 4, 2026, the U.S. Food and Drug Administration (FDA) granted accelerated approval to camizestrant (Etcamah), an estrogen receptor antagonist, in combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) for adults with hormone receptor (HR)-positive, HER2-negative...
Cervical Cancer Nonscreening Increased Over Nearly 2 Decades
Cervical cancer remains a preventable cause of morbidity and mortality, particularly among women who are not reached by screening programs. In a research letter published in JAMA Network Open, Sonawane et al emphasized the importance of identifying those who have never been screened and reported...
Predictors of pCR to Neoadjuvant THP Explored in HER2-Positive Breast Cancer
Secondary analyses of the prospective EA1181/CompassHER2 pCR trial identified clinicopathologic and molecular factors associated with pathologic complete response (pCR) after de-escalated neoadjuvant therapy with a taxane plus trastuzumab and pertuzumab (THP) in patients with stage II to IIIA...
ACS Publishes Report on Cancers in Asian American, Native Hawaiian, and Pacific Islander People
Cancer data for Asian American and Native Hawaiian and Pacific Islander (NHPI) people are usually combined, hiding vast differences in cancer risk. New disaggregated data analyzed by researchers at the American Cancer Society (ACS) show that Native Hawaiian women have a 27% higher breast cancer...
ASCENT-04 Exploratory Analysis: Sacituzumab Govitecan Plus Pembrolizumab Improves PFS2, Delays Next Treatment
First-line treatment with the antibody-drug conjugate sacituzumab govitecan-hziy plus pembrolizumab led to a longer progression-free survival after next line of treatment—ie, progression-free survival–2 (PFS2)—than chemotherapy plus pembrolizumab in patients with previously untreated,...
Additional Safety Analysis of DESTINY-Breast05: What Did It Show?
An additional safety analysis of the global phase III DESTINY-Breast05 trial evaluating the HER2-directed antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) has further established the pulmonary safety profile of T-DXd with radiotherapy, according to Michael Untch, MD, PhD, of Helios...
In Cancer Trials, Federal and Industry Sponsors Play Complementary Roles
A comparative study of the cancer clinical trial portfolios supported by federal funding vs industry funding reveals they have distinct, interdependent roles in cancer research. The findings were published by Unger et al in JAMA Oncology. The analysis found that, whereas industry trials were more...
FDA Approves Zanidatamab Combination Regimens for HER2-Positive Gastric, GEJ, or Esophageal Cancer
On August 25, 2026, the U.S. Food and Drug Administration (FDA) approved zanidatamab-hrii (Ziihera) for two indications, including: in combination with fluoropyrimidine- and platinum-containing chemotherapy and tislelizumab-jsgr (Tevimbra), as first-line treatment for adults with HER2-positive...
The Mid-Career Oncologist in LMIC Regions: Navigating Disparities, Avoiding Burnout, and Delivering Optimal Care
To be a mid-career oncologist is to occupy an emotionally and physically taxing space within a trying clinical environment. We may be 10 years and beyond our post-training. We are no longer trainees who may be protected by institutional shields, nor are we established senior department heads with...
Preoperative Weight-Loss Program Shows Feasibility Before Endometrial Cancer Surgery
A short-term, intensive weight-loss program before surgery was feasible and produced meaningful weight loss in women with endometrial cancer and excess weight in the randomized ENDO-CARE trial. The intervention was also associated with fewer postoperative complications, although the study was not...
Phase III OPTIMA Trial: Many Patients With ER-Positive, HER2-Negative Breast Cancer May Be Able to Avoid Chemotherapy
New results from the international, randomized, phase III OPTIMA trial indicate that select patients with clinically high-risk, estrogen receptor–positive, HER2-negative early breast cancer who have a low risk of recurrence based on tumor gene expression testing may be able to safely avoid...
Consumption of Sugar-Sweetened Beverages May Raise Gastric Cancer Risk
Approximately 65% of U.S. adults report consuming one or more sugar-sweetened beverages every day. Researchers found that consuming these drinks daily was associated with an increased risk of developing gastric cancer, whereas consumption of artificially sweetened beverages was not associated with...
TACE Plus Thermal Ablation Improves Survival in Unresectable HCC
Transarterial chemoembolization (TACE) followed by thermal ablation was associated with improved survival outcomes compared with TACE alone in patients with liver-confined, unresectable hepatocellular carcinoma, according to findings from the phase III TORCH trial published by Lyu et al in JAMA...
FDA Approves Oncolytic Viral Therapy With Immunotherapy for Advanced Melanoma
On August 6, the U.S. Food and Drug Administration (FDA) granted accelerated approval to vusolimogene oderparepvec-wtpg (Tudriqev), a genetically modified oncolytic viral therapy, in combination with nivolumab for the treatment of adult patients with unresectable advanced cutaneous melanoma who...
FDA Approves Radionuclide Therapy Plus ARPI for mAPMN/S Prostate Cancer
On July 31, the U.S. Food and Drug Administration (FDA) approved lutetium-177–labeled PSMA-617 (vipivotide tetraxetan, also known as LuPSMA-617; Pluvicto), a targeted radionuclide therapy, in combination with androgen receptor pathway inhibitor (ARPI) therapy for adults with prostate-specific...
